# Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

> **NCT00336856** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 35 (actual)

## Conditions studied

- Colon Cancer
- Rectum Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00336856
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2016-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336856, "Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00336856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*